KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) EBT (2016 - 2025)

Abbott Laboratories' EBT history spans 17 years, with the latest figure at $2.4 billion for Q4 2025.

  • For Q4 2025, EBT rose 16.16% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $8.5 billion, up 20.72%, while the annual FY2025 figure was $8.5 billion, 20.72% up from the prior year.
  • EBT for Q4 2025 was $2.4 billion at Abbott Laboratories, up from $2.2 billion in the prior quarter.
  • Across five years, EBT topped out at $2.9 billion in Q1 2022 and bottomed at $1.3 billion in Q4 2022.
  • The 5-year median for EBT is $1.9 billion (2023), against an average of $1.9 billion.
  • The largest annual shift saw EBT soared 222.75% in 2021 before it plummeted 45.69% in 2023.
  • A 5-year view of EBT shows it stood at $2.3 billion in 2021, then tumbled by 43.27% to $1.3 billion in 2022, then surged by 35.98% to $1.8 billion in 2023, then grew by 13.09% to $2.0 billion in 2024, then rose by 16.16% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's EBT are $2.4 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.2 billion (Q2 2025).